Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9-ING-41 in Pediatric Refractory Malignancies
NCT04239092Phase 1Terminated
- Sponsor
- Actuate Therapeutics
- Start
- Jun 2020
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elraglusib in cancer, neuroblastoma, pediatric brain tumor and 3 more (4 arms), sponsored by Actuate Therapeutics. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v5. Started Jun 2020; status: terminated.
02
Drugs
elraglusib
03
Conditions
cancerneuroblastomapediatric brain tumorlymphomameningioma
Beyond the preview
Go deeper on NCT04239092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04239092.